Related Experiment Video
Updated: May 21, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Energy depletion in seizures: anaplerosis as a strategy for future therapies
Stjepana Kovac1, Andrey Y Abramov, Matthew C Walker
1UCL Institute of Neurology, University College London, Queen Square, WC1N 3BG London, UK. s.kovac@ion.ucl.ac.uk
Abstract:
Seizure activity can lead to energy failure and neuronal injury, resulting in neurological and cognitive sequelae. Moreover, mutations affecting genes encoding for proteins that maintain energy homeostasis within the cell often result in an epileptic phenotype, implying that energy failure can contribute to epileptogenesis. Indeed, there is evidence to indicate that the efficacy of the ketogenic diet, a treatment for refractory epilepsy, can be partly explained by its effect on increasing energetic substrates. The ATP level, reflecting the energy level of a cell, is maintained by the potential gradient across the mitochondrial membrane. This potential gradient is maintained by NADH/H(+) equivalents, produced by reactions within the tricarboxylic acid cycle (TCA-cycle). Anaplerosis, the replenishment of TCA-cycle substrates, therefore represents an appealing strategy to address energy failure such as occurs in seizures. There is accumulating evidence that pyruvate, a classical anaplerotic substrate, has seizure suppressive effects and protects against seizure induced cell death. This review summarizes the evidence for the contribution of TCA cycle deficits in generating seizures. We highlight the role for TCA substrate supplementation in protecting against seizures and seizure induced cell death, and propose that these are important targets for future translational research addressing energy depletion in seizures. This article is part of the Special Issue entitled 'New Targets and Approaches to the Treatment of Epilepsy'.
Insights
Energy deficits contribute to seizures. Replenishing tricarboxylic acid (TCA) cycle substrates, like pyruvate, may suppress seizure activity and prevent neuronal injury, offering new therapeutic targets for epilepsy.
Area of Science:
- Neuroscience
- Biochemistry
- Epilepsy Research
Background:
- Seizure activity causes energy failure and neuronal damage, leading to cognitive deficits.
- Genetic mutations impacting cellular energy homeostasis are linked to epilepsy.
- The ketogenic diet's efficacy in epilepsy may stem from enhanced energetic substrates.
Purpose of the Study:
- To review the role of tricarboxylic acid (TCA) cycle deficits in seizure generation.
- To highlight TCA substrate supplementation as a potential therapeutic strategy for seizures.
- To explore pyruvate's neuroprotective effects against seizure-induced cell death.
Main Methods:
- Literature review focusing on TCA cycle function in epilepsy.
- Analysis of evidence linking energy metabolism to epileptogenesis.
- Examination of studies on anaplerotic substrate supplementation.
Main Results:
- Evidence suggests TCA cycle deficits contribute to seizure generation.
- Pyruvate demonstrates seizure-suppressive effects and protects against seizure-induced neuronal death.
- Supplementation of TCA cycle substrates shows promise in mitigating seizure-related pathology.
Conclusions:
- Energy failure is a key factor in seizure development and progression.
- TCA cycle anaplerosis, particularly with pyruvate, represents a promising therapeutic avenue.
- Targeting energy depletion in seizures warrants further translational research for epilepsy treatment.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

